Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06125587
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2023-11-09
First Post:
2023-11-05
Brief Title:
ChiglitazarMetformin in Non-obese Women With PCOS
Sponsor:
Shengjing Hospital
Organization:
Shengjing Hospital
Study Overview
Official Title:
Chiglitazar Versus Metformin for Insulin Resistance in Non-obese Patients With Polycystic Ovary Syndrome
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Polycystic ovary syndrome PCOS is the most common endocrine and metabolic disorders in women of reproductive age and its prevalence rate is from 9 NIH criteria to 18 Rotterdamcriteria It is clinically characterized by hyperandrogenism persistent anovulation and polycystic ovarian changes Moreover it is often accompanied by insulin resistance and obesity Now metformin is not only an antihyperglycemic drug it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome Chiglitazar is a novel peroxisome proliferation activated receptor PPAR agonist Treatment of type 2 diabetes mellitus by moderate activation of PPARα PPARγ and PPARδ improving insulin sensitivity regulating blood glucose and promoting fatty acid oxidation and utilization However there is limited evidence for its treatment of insulin resistance in women with PCOS Therefore we applied chiglitazar and metformin to two groups of PCOS patients to understand their effects on insulin resistance
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None